Publications
Parsons JK, Pierce JP, Mohler J, Paskett E, Jung SH, Morris MJ, Small E, Hahn O, Humphrey P, Taylor J, Marshall J. Men's Eating and Living (MEAL) study (CALGB 70807 [Alliance]): recruitment feasibility and baseline demographics of a randomized trial of diet in men on active surveillance for prostate cancer. BJU international. 2017. PMID: 28437029
Daniel Kwon, Claire Mulvey, Alan T Paciorek, Hilary Chan, Lingzhong Meng, Li Zhang, Eric K. Nakakura, Nicholas Fidelman, Emily K. Bergsland, Katherine Van Loon. Periprocedural management of patients undergoing liver resection or liver-directed therapy for neuroendocrine tumor metastases. Journal of Clinical Oncology. 2017. PMID:
Jessica K. Altman, Alexander E. Perl, Jorge E. Cortes, Catherine Choy Smith, Mark Robert Litzow, Jason E Hill, Richard A. Larson, Charles Liu, Ellen K. Ritchie, Stephen Anthony Strickland, Eunice S. Wang, Andreas Neubauer, Giovanni Martinelli, Erkut Bahceci, Mark J. Levis. Deep molecular response to gilteritinib to improve survival in FLT3 mutation-positive relapsed/refractory acute myeloid leukemia. Journal of Clinical Oncology. 2017. PMID:
Victoria Wang, Gabriel N. Mannis, Rebecca Leah Olin, Aaron Logan, Thomas G. Martin, Lloyd Earl Damon, Danielle Kilayko, Pamela N. Munster, Charalambos Andreadis. CyFi: A phase I study exploring the role of cMET pathway inhibition with ficlatuzumab (Fi) combined with high-dose cytarabine (Cy) in patients with high risk relapsed or refractory acute myeloid leukemia (AML). Journal of Clinical Oncology. 2017. PMID:
Michelle E. Melisko, Edward Kenji Hadeler, Sandahl H Nelson, Audrey Lunde, Irene Acerbi, Hope S. Rugo, Melanie Catherine Majure, Amy Jo Chien, Laura Esserman, Sheri J. Hartman. Objective assessment of physical activity during chemotherapy for breast cancer. Journal of Clinical Oncology. 2017. PMID:
Ozawa H, Ranaweera RS, Izumchenko E, Makarev E, Zhavoronkov A, Fertig EJ, Howard JD, Markovic A, Bedi A, Ravi R, Perez J, Le QT, Kong CS, Jordan RC, Wang H, Kang H, Quon H, Sidransky D, Chung CH. SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017. PMID: 28522603
Daud A, Tsai K. Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma. The oncologist. 2017. PMID: 28526719
Hope TA, Aggarwal R, Chee B, Tao D, Greene KL, Cooperberg MR, Feng F, Chang A, Ryan CJ, Small EJ, Carroll PR. Impact of 68Ga-PSMA-11 PET on Management in Patients with Biochemically Recurrent Prostate Cancer. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2017. PMID: 28522741
Huang FW, Mosquera JM, Garofalo A, Oh C, Baco M, Amin-Mansour A, Rabasha B, Bahl S, Mullane SA, Robinson BD, Aldubayan S, Khani F, Karir B, Kim E, Chimene-Weiss J, Hofree M, Romanel A, Osborne JR, Kim JW, Azabdaftari G, Woloszynska-Read A, Sfanos K, De Marzo AM, Demichelis F, Gabriel S, Van Allen EM, Mesirov J, Tamayo P, Rubin MA, Powell IJ, Garraway LA. Exome Sequencing of African-American Prostate Cancer Reveals Loss-of-Function ERF Mutations. Cancer discovery. 2017. PMID: 28515055
Wang VE, Young L, Ali S, Miller VA, Urisman A, Wolfe J, Bivona TG, Damato B, Fogh S, Bergsland EK. A Case of Metastatic Atypical Neuroendocrine Tumor with ALK Translocation and Diffuse Brain Metastases. The oncologist. 2017. PMID: 28507205
Chien AJ, Chambers J, Mcauley F, Kaplan T, Letourneau J, Hwang J, Kim MO, Melisko ME, Rugo HS, Esserman LJ, Rosen MP. Fertility preservation with ovarian stimulation and time to treatment in women with stage II-III breast cancer receiving neoadjuvant therapy. Breast cancer research and treatment. 2017. PMID: 28503722
Ott PA, Bang YJ, Berton-Rigaud D, Elez E, Pishvaian MJ, Rugo HS, Puzanov I, Mehnert JM, Aung KL, Lopez J, Carrigan M, Saraf S, Chen M, Soria JC. Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017. PMID: 28489510
Smith CC, Paguirigan A, Jeschke GR, Lin KC, Massi E, Tarver T, Chin CS, Asthana S, Olshen A, Travers KJ, Wang S, Levis MJ, Perl AE, Radich JP, Shah NP. Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis. Blood. 2017. PMID: 28490572
Tsai KK, Algazi AP. Are PD-1 antibodies safe for use in metastatic uveal melanoma? Melanoma management. 2017. PMID: 30190908
Tsai KK, Algazi AP. Melanoma Management Are PD-1 antibodies safe for use in metastatic uveal melanoma?. 2017. PMID:
Chung A, Hou Y, Ohgami RS, Von Gehr A, Fisk DG, Roskin KM, Li X, Gojenola L, Bangs CD, Arber DA, Fire AZ, Cherry AM, Zehnder JL, Gotlib J, Merker JD. A novel TRIP11-FLT3 fusion in a patient with a myeloid/lymphoid neoplasm with eosinophilia. Cancer genetics. 2017. PMID: 29025582
Golan T, Raitses-Gurevich M, Kelley RK, Bocobo AG, Borgida A, Shroff RT, Holter S, Gallinger S, Ahn DH, Aderka D, Apurva J, Bekaii-Saab T, Friedman E, Javle M. Overall Survival and Clinical Characteristics of BRCA-Associated Cholangiocarcinoma: A Multicenter Retrospective Study. The oncologist. 2017. PMID: 28487467
Garrett SB, Koenig CJ, Trupin L, Hlubocky FJ, Daugherty CK, Reinert A, Munster P, Dohan D. What advanced cancer patients with limited treatment options know about clinical research: a qualitative study. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2017. PMID: 28488050
Martin T, Baz R, Benson DM, Lendvai N, Wolf J, Munster P, Lesokhin AM, Wack C, Charpentier E, Campana F, Vij R. A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma. Blood. 2017. PMID: 28483761
Seward H, Meyer R, Shah N. Iodine Status and Growth in Cow's Milk Allergy. Journal of pediatric gastroenterology and nutrition. 2017. PMID: 28045784